CAR-T cell therapy in China
Treatments available
| Treatments | Status in China | Status in US | Sources |
|---|---|---|---|
| Axicabtagene ciloleucel (Yikaida in China, Yescarta in US) | Approved in China | Approved in China | PubMed CentralNMPA (English) |
| Relmacabtagene autoleucel (Carteyva) | Approved in China | Not approved | PubMed CentralNMPA (English) |
| Equecabtagene autoleucel (Fucaso) | Approved in China | Not approved | Xinhua (English)JW TherapeuticsNMPA (English) |
| Inaticabtagene autoleucel | Approved in China | Not approved | Xinhua (English)NMPA (English) |
| Zevorcabtagene autoleucel | Approved in China | Not approved | Xinhua (English)JW TherapeuticsNMPA (English) |
| Ciltacabtagene autoleucel (Carvykti) | Approved in China | Approved in China | Nature Reviews Drug DiscoveryNMPA (English) |
| Ranicabtagene autoleucel (HICARA) | Approved in China | Not approved | Alliance for Regenerative MedicineShanghai Hengrun Dasheng (Harin Bio)NMPA (English) |
| Satricabtagene autoleucel (satri-cel), Claudin18.2 CAR-T for gastric/GEJ cancer | Approved in China | Not approved | China Economic Net / CailiansheCARsgen TherapeuticsNMPA (English) |
| Dual-target and allogeneic CAR-T (investigational) | Clinical trial | Clinical trial |
Hospitals with documented programs
Informational listings from cited public sources, not recommendations.
Clinical trials
We link trials only; enrollment decisions belong to trial teams. Since May 2026, charging patients to join clinical research is prohibited in China, as reported by AFP.
Frequently asked
Is CAR-T approved in China?
Yes. NMPA approvals began in 2021 (axi-cel and relma-cel). Ranicabtagene became the seventh in July 2025 and satri-cel, for Claudin18.2-positive gastric cancer, was approved in June 2026, per NMPA-linked company announcements.
[1] China Economic Net /…[2] CARsgen TherapeuticsHow does the China list compare with the US?
The FDA had approved seven CAR-T products as of September 2026. Only axi-cel and cilta-cel are approved in both countries; the other China-approved products are not FDA-approved.
[1] BioInformantWhat does CAR-T cost in China?
A journal table lists axi-cel (Yikaida) at about 1.166 million yuan per infusion. AFP reported treatment prices around USD 150,000 to 180,000 in June 2026. A June 2026 NHSA filing says the lymphoma CAR-Ts were not yet in the national basic insurance drug list.
[1] PubMed Central[2] AFP / Free Malaysia …[3] National Healthcare …Can a foreigner access CAR-T in China?
Foreign patients have been treated and publicly reported, for example a New Zealand lymphoma patient in Shanghai. Access runs through hospital international departments or clinical trials; the hospital clinical team decides each case.
[1] AFP / Free Malaysia …Sources
- Redefining CAR-T regulation: China's responses to address secondary cancer risks of CAR-T therapy (Table 1)
“Table 1 lists zevor-cel (NMPA, 2024-02-23), inati-cel (NMPA, 2023-11-07) and eque-cel/Fucaso (NMPA, 2023-06-30).”
- A New Outcomes-Based Payment Plan From a Chinese Company to Improve Patient Affordability of CAR-T Product
“Lists Yikaida (axicabtagene ciloleucel) at about 1.166 million yuan per infusion and inaticabtagene at about 0.999 million yuan.”
- NMPA acceptance of sBLA for Carteyva as second-line treatment in r/r LBCL
“Carteyva has been approved by NMPA for three indications.”
- Harin Bio's CD19 CAR-T HICARA (Ranicabtagene Autoleucel Injection) Approved for Marketing
“On July 30, 2025, the National Medical Products Administration formally approved the New Drug Application for Ranicabtagene Autoleucel Injection (HICARA).”
- Fourth CD19 CAR-T approved in China (seventh CAR-T overall)
“Ranicabtagene became the seventh CAR-T product approved in China.”
- CARsgen Announces Approval of Satri-cel, the World's First CAR T-Cell Therapy Product for Solid Tumors
“Satri-cel is the world's first approved CAR T-cell therapy product for the treatment of solid tumors.”
- Ciltacabtagene Autoleucel Injection Approved for Marketing by China NMPA
“It is indicated for the treatment of adults with relapsed or refractory multiple myeloma after three or more prior lines of therapy and progressed, including a proteasome inhibitor and an immunomodulatory agent.”
- 16 CAR-T Therapies and Counting
“Seven therapies have been approved by the U.S. FDA.”
- 2026 National Reimbursement Drug List application: ranicabtagene autoleucel (public version)
“In r/r large B-cell lymphoma, four CAR-T products are marketed in China (axicabtagene, relmacabtagene, ranicabtagene, inaticabtagene), none yet in the national basic medical insurance drug list.”
Information only. Not medical advice, diagnosis or a treatment recommendation. Talk to your doctor. In an emergency, call your local emergency number.